

**Written Testimony of Edward P. Gelmann, M.D.**

**Presented to the Texas Legislature Senate Committee on Business and Commerce**

**October 9, 2012**

My name is Edward Gelmann. I am Professor of Medicine and of Pathology and I am Chief of the Division of Hematology/Oncology at Columbia University and the New York Presbyterian Hospital. I am also the Deputy Director of the Herbert Irving Comprehensive Cancer Center. I have been a licensed physician for over thirty years, and during that time I have held a number of academic and hospital appointments, which are detailed in my curriculum vitae attached to my written comments. Throughout my career I have cared for patients, taught medical and graduate students, interns, residents and fellows. I have run a research laboratory that focuses on questions about the molecular and genetic origins of cancer. I am familiar with a broad range of peer-reviewed scientific literature examining the potential impacts of electro-magnetic ("EMF") and radio ("RF") frequencies on human beings. I have filed testimony before the Public Utility Commission of Texas on numerous occasions regarding concerns about health effects of electrical and magnetic fields.

I am here today to address concerns about the potential health effects of "Smart Meters," small devices that send electricity use information from customers to the electric utility. Smart Meters measure electricity usage during the entire day and transmit this information to the utility. Transmissions are periodic and very quick, so that during an entire day the Smart Meter is only communicating for about 90 seconds. Smart Meters also can tell a utility when a customer has lost power. I was asked by representatives of

Oncor to provide my opinions regarding the possible health effects of the Smart Meters used in Texas. I am of course being compensated for my time, but my opinions are my own and are consistent with opinions and sworn testimony that I have given in similar matters over the years.

I have reviewed technical materials and met with engineers regarding the properties of the Smart Meters used in Texas. Smart Meters can easily be compared to common household devices such as cordless phones and baby monitors. For example, baby monitors and Smart Meters transmit signals at similar radio frequencies, but baby monitors cause considerably more RF exposure than do Smart Meters since we use baby monitors inside homes and place them near our beds and the beds of our infants.

Smart Meters use some of the same transmission frequencies as cell phones. However, cell phones cause substantially more RF exposure than do Smart Meters since we use them close to our bodies and for much longer periods than 90 seconds a day. Comprehensive exposure studies have been done to determine if there are adverse health effects associated with cell phone use. Those studies have determined that cell phones do not cause human diseases or adverse health effects. Based on comparisons with cell phones alone, it would be hard to see how Smart Meters could be harmful in any way.

It is also important to remember that Smart Meters use transmission frequencies similar to baby monitors, cordless telephones, and cell phones, and all transmit at levels well below the thresholds set by the Federal Communications Commission (“FCC”). Moreover, the Smart Meters used by Oncor only emit RF for a total of about 90 seconds a day.

My review of the scientific, peer-reviewed literature and of the operations of Smart Meters allows me to conclude that there is no convincing evidence that Smart Meters or similar devices can cause any adverse health effects. Moreover, I can say categorically that there is no chance that any of these devices can cause cancer or affect the cancer process.

I understand that you are considering whether a study into the health effects of Smart Meters is warranted. It is my opinion that no such study is necessary. These issues have been looked at many times and have been addressed by numerous independent agencies at the international, national, state, and local levels. Again and again these studies have concluded that there is no credible link between radio transmissions such as those associated with Smart Meters and similar devices and adverse health effects. For example, states such as California, Vermont, and Maine have considered this same issue and each has concluded that Smart Meters are completely safe and that additional study of their safety is not necessary. Additional study of these issues would reach no new conclusions and would expend time and resources that could be expended on other important business in the State of Texas.

I appreciate the opportunity to address this Committee on this important issue, and I look forward to answering your questions at the hearing on October 9, 2012.

Edward P. Gelmann, M.D.

(August, 2012)

**CURRICULUM VITAE**  
(Columbia University Format)

**NAME** Edward Paul Gelmann

**PLACE OF BIRTH** New York, New York

**CITIZENSHIP** U.S.A.

**EDUCATION**

1968-1972 Yale University, New Haven, Connecticut. Scholar of the House, B.S., 1972, magna cum laude.  
1972-1976 Stanford University School of Medicine, Stanford, California, Medical Scientist Training Program. M.D., 1976.

**POSTDOCTORAL TRAINING**

7/1976-6/1978 University of Chicago Hospitals and Clinics, Chicago, Illinois. Intern and Junior Assistant Resident, Department of Internal Medicine. Chairman, Alvin Tarlov, MD.  
7/1978-6/1980 Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, Clinical Associate. Clinical fellowship in medical oncology. Chief, Robert C. Young, MD.  
7/1979-6/1983 Medical Staff Fellow, Laboratory of Tumor Cell Biology, National Cancer Institute, Bethesda, MD.

**LICENSURE**

1977 Illinois State License No. 36-55120 (expired)  
1978 Maryland State License No. D 22807  
California State License No. G 38939 (inactive)  
1988 District of Columbia No. 17431  
2007 New York State 243717

**SPECIALTY BOARD CERTIFICATION**

1977 Diplomat, National Board of Medical Examiners  
1980 Diplomat in Internal Medicine, American Board of Internal Medicine No. 070149  
1982 Subspecialty Certification in Medical Oncology

**UNIFORMED SERVICE**

1978-1988 USPHS; Senior Surgeon (0-5)

## PROFESSIONAL SOCIETIES

American Society for Clinical Investigation  
Fellow, American College of Physicians  
American Association for the Advancement of Science  
American Association for Cancer Research  
American Society of Clinical Oncology

## ACADEMIC APPOINTMENTS

7/1983-9/1988 Senior Investigator, Medicine Branch, National Cancer Institute, Bethesda, Maryland.  
7/1986-10/1988 Adjunct Associate Professor of Microbiology, Georgetown University School of Medicine and Dentistry, Washington, D.C.  
10/1988-1/2007 Professor of Medicine, Professor of Cell Biology, Georgetown University School of Medicine  
10/1988-6/1994 Chief, Division of Medical Oncology, Georgetown University School of Medicine.  
1990-1993 Director, Lombardi Cancer Research Center Urologic Oncology Program  
1993-1999 Director, Lombardi Cancer Center Prostate Cancer Program  
7/1994-12/1995 Chief, Division of Hematology/Oncology, Georgetown University School of Medicine.  
7/1997-6/1998 Vice Chair for Research and Academic Affairs, Department of Medicine, Georgetown University School of Medicine.  
7/1999-1/2007 Chief, Division of Clinical Sciences, Department of Oncology, Georgetown University  
2/2007- Adjunct Professor Medicine and Oncology, Georgetown University.  
2/2007- Professor of Medicine and Pathology, Chief of the Division of Hematology/Oncology, Columbia University and New York Presbyterian Hospital. Deputy Director, Herbert Irving Comprehensive Cancer Center.  
2/2009 Adjunct Professor of Medicine, Weill Cornell Medical College

## HOSPITAL APPOINTMENTS

10/1988- Georgetown University Hospital, Washington, DC  
7/1996-6/97 Shady Grove Adventist Hospital, Rockville, MD  
4/2007- New York Presbyterian Hospital, New York, NY

## HONORS AND AWARDS

1970 Phi Beta Kappa  
1988 Unit Commendation, United States Public Health Service  
1991 American Society for Clinical Investigation  
1992 Outstanding Visit Award, Department of Medicine, Georgetown University School of Medicine  
2002 William M. Scholl Chair in Medical Oncology, Georgetown University School of Medicine  
2007 Clyde Wu Professor of Oncology, Columbia University

## FELLOWSHIP AND GRANT SUPPORT

### GRANTS: current

11/1/2011-2016 National Cancer Institute  
P01 CA154293  
Molecular Mechanism of Prostate Cancer Initiation  
PI- Michael Shen  
Project 3, Role of the DNA Damage, Core A - E Gelmann,  
Total Costs for Project - \$1,475,000; Core - \$629,000

1/1/2011-2013 Department of Defense - PC100082  
Targeting Kinases in Prostate Cancer  
PI- Edward Gelmann  
Total Costs - \$ 730,000

### GRANTS: expired

12/1/2006-10 Department of Defense - PC061532  
NKX3.1 Genotype and IGF-1 Interact in Prostate Cancer Risk, PI- Edward  
Gelmann  
Total Costs - \$ 582,000

09/1/03-8/31/08 National Institute of Environmental Health Sciences, R01 ES09888 Genetic  
Polymorphism in Prostate Cancer (Years 05-09 of R01)  
PI - Edward Gelmann, Total Costs \$900,000

10/1/05-9/30/08 Department of Defense  
The Role of Inflammatory Cytokines in Prostate Cancer Initiation, PI – Mark  
Markowski  
Predoctoral training grant, Mentor – Edward Gelmann

3/1/2006-2/28/2007 Prostate Cancer Foundation  
Interaction of Prostate Cancer Risk Factors  
PI – Edward Gelmann  
Total Costs - \$100,000.

07/1/02-6/30/06 National Cancer Institute, R01 CA96854  
 $\beta$ -Catenin in Prostate Cancer  
PI - Edward Gelmann, Total Costs \$884,640

4/1/90 - 3/31/93 National Cancer Institute  
Molecular Mechanisms for Prostate Cancer Cell Growth, R01-CA50355, PI -  
Edward Gelmann, 10% effort. Total direct costs: \$567,056.

7/1/90 - 6/30/93 American Cancer Society  
Clinical Oncology Fellowship. PI - Edward Gelmann. Total direct costs:  
\$10,000.

10/1/92 - 9/30/95 National Cancer Institute  
SPORE in Prostate Cancer. Developmental Grant 1-P20-CA58189. PI -  
Edward Gelmann, 5% effort. Total costs: \$ 225,000.

7/1/93 - 6/30/95 National Cancer Institute  
Inhibition of Heparin-Binding Growth Factors, R01-CA57406. PI - Anton  
Wellstein, Co-PI Edward Gelmann, 5% effort. Total direct costs: \$835,989.

1993-1995 Janssen Corporation, Randomized trial of liarozole versus prednisone for  
metastatic prostate cancer. 5% effort. Total costs: \$72,000.

7/1/92 - 6/30/97 National Cancer Institute  
Markers for Malignant Progression in Prostate Cancer, U01-CA57178, PI - Edward Gelmann, 10% effort. Total direct costs: \$498,808.

7/1/93 - 6/30/97 National Cancer Institute  
Cancer Center Support Grant, P30 - CA51008, PI - Marc Lippman. 10% effort: Director, Prostate Cancer Program, Total direct costs: \$2,408,218.

12/1/93-11/30/94 CaP CURE Foundation  
Research in Prostate Cancer, PI - Edward Gelmann. Total Costs: \$200,000.

1/1/97-1/98 Janssen Pharmaceuticals  
Phase II trial of liarozole and prednisone in hormone-refractory prostate cancer. PI- Edward Gelmann. Total Costs \$50,000.

1/1/97-1/98 Janssen Pharmaceuticals  
Phase II trial of liarozole in newly relapse local prostate cancer. PI - Edward Gelmann. Total Costs \$50,000.

12/1/94-11/30/95 CaP CURE Foundation  
Research in Prostate Cancer, PI - Edward Gelmann. Total Costs \$100,000.

12/1/95-11/30/96 CaP CURE Foundation  
Research in Prostate Cancer, PI - Edward Gelmann. Total Costs \$100,000.

12/1/96-11/30/97 CaP CURE Foundation  
Research in Prostate Cancer, PI - Edward Gelmann. Total Costs \$50,000.

07/1/98-9/1/98 Glaxo-Wellcome  
Phase II Evaluation of Humanized Monoclonal Antiepithelial Antibody in Patients with Early Relapse of Prostate Cancer. PI - Edward Gelmann.

06/1/98-5/30/00 National Cancer Institute  
NKX3.1 in Prostate Cancer, R21CA78327  
PI - Edward Gelmann, Total Costs, \$313,000

07/1/98-12/31/00 Agouron Corporation  
Randomized Trial to Assess AG3340 in Patients with Hormone-Refractory Prostate Cancer. PI - Edward Gelmann, Total Costs - \$80,000.

10/1/98-3/31/01 DOD - Prostate Cancer Research Program - PC000016  
NKX3.1 in Prostate Cancer, PI - Edward Gelmann  
Total Costs - \$393,750

1/1/98-12/31/01 National Cancer Institute, R01 CA79912  
Apoptosis in Prostate Cancer Cells, PI - Edward Gelmann  
Total Costs - \$640,83

06/01/00-05/31/02 National Cancer Institute, R21-CA87855  
 $\beta$ -Catenin in Prostate Cancer, PI – Edward Gelmann  
Total Costs - \$312,000

4/01/01-3/31/03 Department of Defense – PC 000016 phase II  
NKX3.1 in Prostate Cancer, PI – Edward Gelmann  
Total Costs - \$738,559

7/01/01-6/30/03 National Cancer Institute, R21 CA87855  
 $\beta$ -Catenin in Prostate Cancer, PI - Edward Gelmann  
Total Costs - \$312,000

11/1/01-10/31/04 Department of Defense PC-010281

Genetic Risk Factor for Prostate Cancer, PI Edward Gelmann  
Annual Direct Costs - \$114,220

7/1/03-6/30/07 National Cancer Institute, R01 CA100743-01 Molecular Epidemiology of Fatal Prostate Cancer, PI – Shiela Weinmann, PhD; Edward Gelmann PI of subcontract, Total Costs \$500,000 (13.3%ile, awaiting funding).

10/1/93-9/30/08 National Cancer Institute  
Prostate, Lung, Colon, and Ovarian Cancer Screening Trial. 1-N-01-CN25522-00, PI - Edward Gelmann. 35% Effort. Total costs \$21,040,000.

4/1/02-3/30/07 National Cancer Institute  
Cancer Center Support Grant  
PI – Anatoly Dritschilo  
Director of Cancer Center Core Facility – Clinical Research Management Office.  
Director – Program in Growth Regulation of Cancer

4/1/03-03/31/09 Cancer and Acute Leukemia Group B (CALGB) Institutional Grant 1U10 CA77597, PI – Edward Gelmann  
Annual Direct Costs - \$107,873

#### **DEPARTMENTAL AND UNIVERSITY COMMITTEES**

1989-1995 Research Committee

1989-1992 Pharmacy Committee, Georgetown University Hospital

1989-1994 Committee on Faculty, Georgetown University Medical Center

1989-1995 Bone Marrow Transplantation Committee

1989-1995 Executive Committee, Lombardi Cancer Research Center

1990-1993 Cancer Committee, Georgetown University Hospital

1991-1992 Task Force for Clinical Research, Chairman, Subcommittee for Clinical/Basic Science Department Interactions

1992-1993 Committee on Appointments and Promotions, Department of Medicine

1993-1995 Chairman, Department of Medicine Committee on Appointments and Promotions

1994 Subcommittee on Research Space, Research Committee

1995-1997 Department of Medicine Committee on Appointments and Promotions

1996-1997 Lombardi Cancer Center Clinical Research Committee

1996-1997 Medical Director, Lombardi Cancer Center satellite at Shady Grove.

1996- Committee on Admissions and Mentorship for MD-PhD Program

1996-2002 Chemotherapy Oversight Committee, Georgetown University Hospital

1996 Chair, Faculty Content Task Force, Department of Medicine

1997-2005 Research Committee

1997-2005 Committee on Faculty, Georgetown University Medical Center

1998-2003 GCRC Advisory Committee

1999- Lombardi Cancer Center Clinical Research Committee

1998- Lombardi Cancer Center Executive Committee

2002-2005 Chair, Committee on Appointments and Promotions, Georgetown University School of Medicine (Promotion and Tenure Committee)

2008 Chair, Committee to Review Research Pharmacy, Columbia University

2008- Chair, Research Pharmacy Oversight Committee, Columbia University



## TEACHING ACTIVITIES

- 1988-1995 Director, Subspecialty Training Program in Medical Oncology, Department of Medicine, Georgetown University School of Medicine.  
2008 Lectures in Pathophysiology, Columbia University College of Physicians and Surgeons  
2008 Lectures in Advanced Pathophysiology, Columbia University College of Physicians and Surgeons

### PhD Thesis Committees

- 1993 Department of Cell Biology. Stephen Seslar. The role of HGF in the growth of breast cancer cells.  
1994 Department of Biochemistry and Molecular Biology. Ronit Yarden. Bimodal regulation of EGF receptor by estrogen in breast cancer cells.  
1997 Department of Cell Biology. Beth Pflug. Role of NGF and NGF receptor in the growth of prostate cancer cell lines.  
1997 Department of Biochemistry and Molecular Biology. Jainming Liu. Intereaction of androgen receptor with SV40 T antigen.  
1998 Department of Biochemistry and Molecular Biology. Kevin McGaffin. Vitamin D control of EGF receptor expression in breast cancer.  
1998 Department of Cell Biology. Keith Orford. Degradation and Processing of  $\beta$ -Catenin.  
2000 Department of Cell Biology. Christine Jarret. The Roles of APC2 and IKK in the Regulation of  $\beta$ -catenin Signaling.  
2000 Department of Oncology. Jen-Kang Wang. Apoptosis in transgenic breast cancer cells expressing *MYC*.  
2001 Department of Oncology. Roger Herold. Interaction of  $\beta$ -catenin and retinoic acid receptor.  
2002 Thesis examiner, Paul Hollington, Flinders University, Adelaide, S. Australia.  
2003 Thesis examiner, Lisa Horvath, University of New South Wales, NSW, Australia  
2004 Department of Oncology. Jamie Holloway. The regulation of the estrogen receptor and its coactivator, AIB1, by growth factor signaling.  
2006 Department of Oncology. Lynn Nielson. The role of prolactin in breast cancer cell invasion.  
2006 Department of Oncology. Aparna Mani. Ubiquitination of the Steroid Hormone Coactivator AIB1.

### PhD Thesis Advisor

- Mark Markowski (MD, PhD) – Inflammatory Cytokines Induce Ubiquitination and Loss of The Prostate Suppressor Protein NKX3.1, Georgetown University, 2008  
Erin Muhlbradt (PhD) – The role of IGFBP-3 in Mediating NKX3.1 Tumor Suppression, Georgetown University, 2009

Lectures in courses of the Tumor Biology Training Program.

## OTHER PROFESSIONAL ACTIVITIES

- 1981-1983 Institutional Review Board, Clinical Oncology Program/DCT/NCI  
1985-1990 Editorial Board, *Blood*

1983- Ad hoc reviewer: *Annals of Internal Medicine*  
*Cancer Research*  
*Journal of Clinical Oncology*  
*Journal of the National Cancer Institute*  
*Molecular Endocrinology*  
*International Journal of Cancer*  
*New England Journal of Medicine*

1984-1986 National Cancer Institute Clinical Research Subpanel

1985-1987 National Cancer Institute Technical Review Committee for Contracts

1988, 1989 Program Committee - American Society of Clinical Oncology

1989-2004 American Society of Clinical Oncology Liaison to National Cancer Advisory Board

1989-1993 Study section member: Microbiology and Infectious Diseases Research Committee, NIAID, NIH

1991-1994 Study section ad hoc reviewer: for Metabolic Pathology Study Section, NCI

1991 Chair, NCI site visit for program project grant (P01), University of Arizona, Tuscon, AZ.

1992- Prostate, Lung, Colon and Ovarian (PLCO) Cancer Screening Trial Steering Committee

1992 Chair, NCI Special Study Section for program project grant (P01), University of Arizona, Tuscon, AZ.

1993 Special review committee for program project grant supplement, NCI.

1994-1997 Study section member: Metabolic Pathology Study Section

1994 Special review committee for R01 grant

1993-1999 Scientific Advisory Board, CaPCure Foundation

1996- Chair, Ancillary Studies Committee, Prostate, Lung, Colon and Ovarian Cancer Screening Trial

1997- Editorial Board, *The Prostate Journal*

1997-1999 Editorial Board, *Cancer Therapeutics*

1998 Correlative Sciences Subcommittee, Cancer and Leukemia Group B

1999 National Advisory Council, Horace Mann School, Riverdale, NY.

2000 Study Section member, Cancer Center Support Grant, Robert H. Lurie Cancer Center, Northwestern University, Chicago, IL.

2003 Study Section member, NIDDK, George O'Brien Centers for Urologic Research.

2003 Review committee member for quadriennial evaluation - Laboratory of Molecular Biology, National Cancer Institute

2004-05 American Society of Clinical Oncology 2004, 05 Annual Meeting Program Committee

2003 Contributing author *Medical Oncology- Medical Knowledge Self-Assessment Program (MKSAP)*

2004-06 Organizer and Chair Course in Molecular Oncology, American Society of Clinical Oncology Annual Meeting, New Orleans, LA.

2003-07 Chair, Biomolecular Studies Committee, Prostate, Lung, Colon, and Ovarian Cancer Screening Trial.

2004- Editorial Board, *Cancer Research*

2005-08 American Society of Clinical Oncology, Cancer Education Committee

2005 Ad Hoc Review Committee for NCI

2005 Chair, CDMRP Review Panel for Prostate Cancer Clinical Research Centers.

2005 Program Committee, American Association for Cancer Research 2006 Annual Meeting

2005-206 American Society of Clinical Oncology Education Committee – Compendium Editorial Board

2005- External Advisory Board, SPORE in Prostate Cancer, Dana Farber Cancer Institute.

2006 Member, Study Section for site visit of program project grant, Vancouver General

- Hospital, Vancouver, BC for NCI Canada.
- 2006-2007 External Advisory Board, application for SPORE in Prostate Cancer, New Jersey Cancer Institute
- 2006 Study Section member, P30 Cancer Center application, Case Western Reserve University, Cleveland, OH.
- 2008 Study Section for George M. O'Brien Urologic Research Centers, NIDDK, NIH.
- 2008 Chair, CDMRP Review Panel for Prostate Cancer Research Grants.
- 2008- Editorial Board, *Journal of Clinical Oncology*

## BIBLIOGRAPHY

\*indicates senior author publication

### Original, Peer Reviewed Articles

1. Gelmann, E.P., and Cronan, J.E.: Mutant of Escherichia coli deficient in the synthesis of cis-vaccenic acid. *J Bacteriol.* 112:381-387, 1972.
2. Cronan, J.E., and Gelmann, E.P.: An estimate of the minimum amount of unsaturated fatty acid required for the growth of Escherichia coli. *J Biol Chem.* 248:1181-1195, 1973.
3. Declève, A., Niwa, O., Gelmann, E.P., and Kaplan, H.S.: Kinetics of propagation of B-tropic murine leukemia virus on Fv-1b cell lines: requirement for multiple cycles of cell replication for transformation and viral antigen expression. *Virology* 65:320-332, 1975.
4. Declève, A., Niwa, O., Gelmann, E.P., and Kaplan, H.S.: Replication kinetics of N- and B-tropic murine leukemia viruses on permissive and nonpermissive cells in vitro. *Virology* 65:320-332, 1975.
5. Gelmann, E.P., and Steward, J.P.: Faculty and students as admissions interviewers: results of a questionnaire given to applicants. *J Med Educ.* 50:626-628, 1975.
6. Cronan, J.E., and Gelmann, E.P.: Physical properties of membrane lipids: biological relevance and regulation. *Bacteriol Rev.* 39:232-256, 1975.
7. Gelmann, E.P., and Steward, J.P.: Admissions interviews. (Letter to the Editor) *J Med Educ.* 50:1078-1079, 1975.
8. Gelmann, E.P., Niwa, O., Declève, A., and Kaplan, H.S.: X-ray potentiation of MuLV infection in vitro. *Virology* 69:561-569, 1976.
9. Gelmann, E.P., Declève, A., and Kaplan, H.S.: Biological and biochemical differences among ecotropic C-type RNA viral isolates chemically induced from C57Bl/Ka mouse embryo cells in vitro. *Virol.* 85:198-210, 1978.
10. Gelmann, E.P., Wong-Staal, F., Kramer, R.A., and Gallo, R.C.: Molecular cloning and comparative analyses of the genomes of simian sarcoma virus (SSV) and its associated helper virus (SSAV). *Proc Nat Acad Sci, USA.* 78:3373-3377, 1981.
11. Wong-Staal, F., Dalla-Favera, R., Franchini, G., Gelmann, E.P., and Gallo, R.C.: Three distinct genes in human DNA related to the transforming genes of mammalian sarcoma retroviruses. *Science* 213:226-228, 1981.
12. Dalla-Favera, R., Gelmann, E.P., Gallo, R.C., and Wong-Staal, F.: A human onc gene homologous to the transforming gene (v-sis) of simian sarcoma virus. *Nature* 295:31-35, 1981.
13. Weinstein, R.A., Golomb, H.M., Grumet, G., Gelmann, E.P., and Schechter, G.P.: Hairy cell leukemia:

- Association with disseminated atypical mycobacterial infection. *Cancer* 48:380-383, 1981.
14. Wong-Staal, F., Dalla-Favera, R., Gelmann, E.P., Manzari, V., Szala, S., Josephs, S., and Gallo, R.C.: The transforming gene of simian sarcoma virus is a new onc gene of primate origin. *Nature* 294:273-275, 1981.
  15. Gelmann, E.P., and Dennis, L.H.: Plasma-cell dyscrasia after alkylating-agent therapy for Hodgkin's disease. *New Engl J Med.* 305:1350, 1981.
  16. Gelmann, E.P., Petri, E., Cetta, A., and Wong-Staal, F.: Deletions of specific regions of the simian sarcoma associated virus genome are found in defective viruses and the simian sarcoma virus. *J Virol.* 41:593-604, 1982.
  17. Westin, E.H., Wong-Staal, F., Gelmann, E.P., Dalla-Favera, R., Papas, T.S., Lautenberger, J., Eva, A., Reddy, E.P., Tronick, S.R., Aaronson, S.A., and Gallo, R.C.: Expression of cellular homologs of retroviral onc genes in human hematopoietic cells. *Proc Nat Acad Sci, USA* 79:2490-2494, 1982.
  18. Franchini, G., Gelmann, E.P., Dalla-Favera, R., Gallo, R.C., and Wong-Staal, F.: A human gene (c-fes) related to the onc sequences of Synder-Theilen feline sarcoma virus. *Mol Cell Biol.* 2:1014-1019, 1982.
  19. Gelmann, E., Trainor, C., Wong-Staal, F., and Reitz, M.: Molecular cloning of circular unintegrated DNA of two forms of gibbon ape leukemia virus - Seato. *J. Virol.* 44:269-275, 1982.
  20. Dalla-Favera, R., Gelmann, E.P., Martinotti, S., Franchini, G., Papas, T.S., Gallo, R.C., and Wong-Staal, F.: Cloning and characterization of different human sequences related to the onc gene (v-myc) of avian myelocytomatosis virus (MC-29). *Proc Nat Acad Sci, USA* 79:6497-6501, 1982.
  21. Josephs, S.F., Dalla-Favera, R., Gelmann, E.P., Gallo, R.C., and Wong-Staal, F.: 5' Viral and human cellular sequences corresponding to the transforming gene of simian sarcoma virus. *Science* 219:503-505, 1983.
  22. Gelmann, E.P., Josephs, S., and Wong-Staal, F.: Two strains of baboon endogenous virus demonstrate a high degree of genetic conservation. *Gene* 21:163-166, 1983.
  23. Manzari, V., Wong-Staal, F., Franchini, G., Colombini, Gelmann, E.P., Oroszlan, S., Staal, S., Gallo, R.C.: Human T-cell leukemia-lymphoma virus (HTLV). Cloning of an integrated defective provirus and flanking cellular sequences. *Proc Nat Acad Sci, USA* 80:1574-1578, 1983.
  24. Wong-Staal, F., Hahn, H., Manzari, V., Colombini, S., Franchini, G., Gelmann, E., and Gallo, R.C.: A survey of human leukemias for sequences of a human retrovirus, HTLV. *Nature* 302:626-628, 1983.
  25. Gelmann, E.P., Popovic, M., Blayney, D., Masur, H., Sidhu, G., Stahl, R.E., and Gallo, R.C.: Human retrovirus, HTLV, proviral DNA in lymphocytes of two patients with acquired immune deficiency syndrome (AIDS). *Science* 220:862-865, 1983.
  26. Gallo, R.C., Sarin, P.S., Gelmann, E.P., Robert-Guroff, M., Richardson, E., Kalyanaraman, V.S., Mann, D., Sidhu, G.D., Stahl, R.E., Leibowitch, J., and Popovic, M. Isolation of human T-cell leukemia virus (HTLV) in acquired immune deficiency syndrome (AIDS). *Science* 220:865-868, 1983.
  27. Gelmann, E.P., Clanton, D.J., Jariwalla, R.J., and Rosenthal, L.J.: Characterization and location of myc-related sequences in human cytomegalovirus. *Proc Nat Acad Sci, USA* 80:5107-5111, 1983.
  28. Clark, M., Gelmann, E.P., and Reitz, M.S.: Homology of the human T-cell leukemia virus envelope gene with a class-1 major histocompatibility antigen gene. *Nature* 304:60-62, 1983.

29. Gelmann, E.P., Psallidopoulos, M., Papas, T., and Dalla-Favera, R.: Identification of reciprocal translocation sites within the c-myc onc gene and immunoglobulin  $\mu$  locus in a Burkitt lymphoma. *Nature* 306:799-803, 1983.
30. Gelmann, E.P. Possible role for retroviruses, pp. 103-104 in Fauci, A.S. (moderator): Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations. *Ann Int Med.* 100:92-106, 1984.
31. Gelmann, E.P., Franchini, G., Manzari, V., Wong-Staal, F., and Gallo, R.C.: Molecular cloning of a new unique human T-leukemia virus (HTLV-11Mo). *Proc Nat Acad Sci, USA* 81:993-997, 1984.
32. Longo, D.L., Gelmann, E.P., Cossman, J., Young, R.A., Gallo, R.C., O'Brien, S., and Matis, L.A.: The isolation of a human T-cell leukemia/lymphoma virus (HTLV) transformed B-lymphocyte clone from a patient with HTLV-associated adult T-cell leukemia. *Nature* 310:505-506, 1984.
33. Sodroski, J., Trus, M., Perkins, D., Patarca, R., Wong-Staal, F., Gelmann, E.P., Gallo, R.C., Haseltine, W.: Repetitive structure in the long-terminal-repeat element of a type II human T-cell leukemia virus. *Proc Nat Acad Sci, USA* 31:4617-4621, 1984.
34. Robert-Guroff, M., Blayney, D.W., Safai, B., Lange, M., Gelmann, E.P., Gutterman, J.W., Mansell, P.W.A., Goedert, J.L., Groopman, J.E., Steigbigel, N.H., Sidhu, G.S., Johnson, J.W., Friedman-Kien, A.E., Downing, R., Bayley, A.C., Gallo, R.C.: HTLV-I-specific antibody in AIDS patients and others at risk. *Lancet* ii, 128-130, 1984.
35. Gelmann, E.P., Burny, A., Kettmann, R.: Characterization of cellular sequences flanking an integrated bovine leukemia virus genome. *J Virol.* 52:988-990, 1984.
36. Rustgi, V., Hoofnagle, J., Gerin, J., Gelmann, E.P., Reichert, C., Cooper, J., and Macher, A.: Hepatitis B virus infection in the acquired immunodeficiency syndrome. *Ann Int Med.* 101:795-797a, 1984.
37. Pass, H.I., Potter, D.A., Macher, A.M., Reichert, C., Shelhamer, J.H., Masur, H., Ognibene, F., Gelmann, E.P., Lane, H.C., Fauci, A., and Roth, J.A.: Thoracic manifestations of the acquired immune deficiency syndrome. *J Thoracic and Cardiovasc Surg.* 88:564-658, 1984.
38. Smith, P.D., Macher, A., Bookman, M., Boccia, R., Steis, R., Gill, V., Manischewitz, J., and Gelmann, E.P.: Salmonella typhimurium enteritis and bacteremia in the acquired immunodeficiency syndrome. *Ann Int Med.* 102:207-209, 1985.
39. Whang-Peng, J., Budd, P.A., Knutsen, T., Kao-Shan, C.S., Broder, S., Jaffe, E., Gelmann, E.P., Blattner, W., Lofters, W., Young, R.C., and Gallo, R.C.: Cytogenetic studies in human T-cell lymphoma virus (HTLV) positive leukemia/lymphoma in the USA. *J Nat Cancer Inst.* 74:357-369, 1985.
40. Lane, H.C., Siegal, J., Rook, A.H., Masur, H., Gelmann, E.P., Quinnan, G.V., and Fauci, A.S.: Use of interleukin-2 in patients with the acquired immunodeficiency syndrome (AIDS). *J Biol Response Modifiers* 3:512-516, 1984.
41. Boccia, R.V., Gelmann, E.P., Baker, C.C., Marti, H., and Longo, D.L.: A hemolytic uremic syndrome with the acquired immunodeficiency syndrome. *Ann Int Med.* 101:716-717, 1984.
42. Lane, H.C., Masur, H., Gelmann, E.P., Longo, D.L., Steis, R.G., Chused, T., Walen, G., Edgar, L., and Fauci, A.S.: Immunologic profiles define clinical subpopulations of patients with the acquired immunodeficiency syndrome. *Am J Med.* 78:417-422, 1985.

43. Papadopoulos, N.M., Lane, H.C., Costello, R., Moutsopoulos, H.M., Masur, H., Gelmann, E.P., and Fauci, A.S.: Oligoclonal immunoglobulins in patients with the Acquired Immunodeficiency Syndrome. *Clin Immunol and Immunopathol.* 35:43-6, 1985.
44. Gelmann, E.P., Preble, O.T., Steis, R., Lane, H.C., Rook, A.H., Wesley, M., Jacob, J., Fauci, A., Masur, H., and Longo, D.: Human lymphoblastoid interferon treatment of Kaposi's sarcoma in AIDS: clinical response and prognostic parameters. *Am J Med.* 78:737-741, 1985.
45. \*Preble, O.T., Rook, A.H., Steis, R., Silverman, R.H., Krause, D., Quinnan, G.V., Masur, H., Jacob, J., Longo, D., and Gelmann, E.P.: Interferon-induced 2'-3'-oligoadenylate synthetase during alpha interferon therapy in homosexual men with Kaposi's sarcoma: marked deficiency in the biochemical response to interferon in AIDS patients. *J Infect Dis.* 152:457-465, 1985.
46. Broder, S., Yarchoan, R., Collins, J.M., Lane, H.C., Markham, P.D., Klecker, R.W., Redfield, R.R., Mitsuya, H., Hoth, D.F., Gelmann, E., et al: Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivo. *Lancet* 2:627-630, 1985.
47. Rook, A., Manischewitz, J., Frederick, W., Epstein, J., Jackson, L., Gelmann, E.P., Steis, R., Masur, H., and Quinnan, G.: Deficient HLA-restricted, cytomegalovirus-specific cytotoxic T lymphocytes and natural killer cells in patients with AIDS. *J Infect Dis.* 152:627-630, 1985.
48. Siegel, J.P., Djeu, J.Y., Stocks, N.I., Masur, H., Gelmann, E.P., Quinnan, G.V., Jr.: Sera from patients with the acquired immunodeficiency syndrome inhibit production of interleukin-2 by normal lymphocytes. *J Clin Invest.* 75:1957-1964, 1985.
49. \*Kasid, A., Lippman, M.E., Papageorge, A., Lowy, D., and Gelmann, E.P.: Harvey murine sarcoma virus DNA transfected into MCF-7 human breast cancer cells bypasses their dependence on estrogen for tumorigenicity. *Science* 228:725-728, 1985.
50. Ognibene, F., Steis, R., Macher, A., Liotta, L., Gelmann, E.P., Pass, H., Lane, C., Fauci, A., Parrillo, J., Masur, H., and Shelhamer, J.: Kaposi's sarcoma causing pulmonary infiltrates and respiratory failure in the acquired immunodeficiency syndrome. *Ann Int Med.* 102:471-475, 1985.
51. \*Kleinerman, E., Ceccorulli, L., Zwelling, L., Twilley, T., Herberman, R., Jacob, J., and Gelmann, E.: Activation of monocyte-mediated tumoricidal activity in patients with the acquired immunodeficiency syndrome. *J Clin Oncol.* 3:1005-1012, 1985.
52. Gelmann, E.P.: New concepts in Kaposi's sarcoma pp. 804-805. In: Fauci, A.S., Moderator. The acquired immunodeficiency syndrome: An update. *Ann Int Med.* 102:800-813, 1985.
53. Lecatsas, G., Houff, S., Macher, A., Gelmann, E.P., Steis, R., Reichert, C., Masur, H., and Sever, J.L.: Retrovirus-like particles in salivary, prostate and testes of AIDS patients. *Proc Soc Exp Biol Med.* 178:653-655, 1985.
54. Frederick, W., Epstein, J., Gelmann, E.P., Rook, A.H., Armstrong, G., Djeu, J.Y., Jackson, L., Manischewitz, J., Enterline, J., Jacob, J., Masur, H., and Quinnan, G.V.: Viral infections and cell-mediated immunity in immunodeficient homosexual men with Kaposi's sarcoma treated with human lymphoblastoid interferon. *J Infect Dis.* 152:162-170, 1985.
55. Broder, S., Yarchoan, R., Collins, J., MacKham, P., Klecker, R., Redfield, R., Mitsuya, H., Hoth, D., Gelmann,

- E., Groopman, J., Resnick, L., Gallo, R.C., Myers, C., and Fauci, A.: Effects of suramin in HTLV-III/LAV infection representing as Kaposi's sarcoma or AIDS-related complex: Clinical pharmacology and suppression of virus replication in vivo. *Lancet* ii 627-630, 1985.
56. Kovacs, J.A., Kovacs, A.A., Polis, M., Wright, W.C., Gill, V.J., Tuazon, C.V., Gelmann, E.P., Lane, H.C., Longfield, R., Overturf, G., Macher, A.M., Fauci, A.S., Parrillo, J.E., and Bennett, J.E.: Cryptococcosis in the acquired immunodeficiency syndrome. *Ann Int Med.* 103:533-538, 1985.
  57. \*Masur, H., Lane, H.C., Palestine, A., Smith, P.D., Manischewitz, J., Stevens, G., Fujikawa, L., Macher, A., Nussenblatt, R., Baird, B., Megill, M., Wittek, A., Quinnan, G., Parrillo, J.E., Rook, A., Eron, L., Poretz, D., Goldberg, R., Fauci, A., and Gelmann, E.P.: Effects of 9-(1,3 dihydroxy-2propoxymethyl) guanine on serious cytomegalovirus disease in eight immunosuppressed homosexual men. *Ann Int Med.* 104:41-44, 1986.
  58. Palestine, A., Stevens, G., Lane, H.C., Masur, H., Fujikawa, L., Nussenblatt, R.B., Rook, A., Manischewitz, J., Baird, B., Megill, M., Quinnan, G., Gelmann, E.P., and Fauci, A.S.: Treatment of cytomegalovirus retinitis with dihydroxypropoxymethyl guanine. *Am J Ophthalmol.* 101:95-101, 1986.
  59. \*Stein, C., Saville, W., Yarchoan, R., Broder, S., and Gelmann, E.P.: Suramin and function of the adrenal cortex. *Ann Int Med.* 104:286-287, 1986.
  60. Davidson, N.E., Bronzert, D.A., Chambon, P., Gelmann, E.P., and Lippman, M.E.: Use of two MCF-7 cell variants to evaluate the growth regulatory potential of estrogen-induced products. *Cancer Res.* 46:1904-1908, 1986.
  61. Kasid, A., Davidson, N.E., Gelmann, E.P., and Lippman, M.E.: Transcriptional control of thymidine kinase gene expression by estrogen and antiestrogens in MCF-7 human breast cancer cells. *J Biol Chem.* 261:5562-5567, 1986.
  62. Yarchoan, R., Klecker, R.W., Weinhold, K.J., Markham, P.D., Lyster, H.K., Durack, D.T., Gelmann, E., Lehrman, S.N., Blum, R.M., Barry, D.W., et al: Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. *Lancet* 1:575-580, 1986.
  63. Pass, H.I., Potter, D., Shelhammer, J., Macher, A., Ognibene, F., Longo, D., Gelmann, E.P., Masur, H., and Roth, J.: Indications for and diagnostic efficacy of open-lung biopsy in patients with the acquired immunodeficiency syndrome (AIDS). *Ann Thor Surg.* 41:307-312, 1986.
  64. Heckford, S.E., Gelmann, E.P., Agnor, C.L., Jackson, S., Zinn, S., Matis, L.A.: Distinct signals are required for proliferation and lymphokine gene expression in murine T cell clones. *J Immunol.* 137:3652-3663, 1986.
  65. Lippman, M.E., Dickson, R.B., Bates, S., Knabbe, C., Huff, K., Swain, S., McManaway, M., Bronzert, D., Kasid, A., and Gelmann, E.P.: Autocrine and paracrine growth regulation of human breast cancer. *Breast Cancer Res. Treat.* 7:59-70, 1986.
  66. Watkins, E.B., Findlay, P., Gelmann, E., Lane, H.C., Zabell, A.: Enhanced mucosal reactions in AIDS patients receiving oropharyngeal irradiation. *Int J Radiat Oncol Biol Phys* 13:1403-1408, 1987.
  67. Lippman, M.E., Dickson, R.B., Gelmann, E.P., Rosen, N., Knabbe, C., Bates, S., Bronzert, D., Huff, K., and Kasid, A.: Growth regulation of human breast carcinoma occurs through regulated growth factor secretion. *J Cellular Biochem* 35: 1-16, 1987.
  68. Lippman, M.E., Dickson, R.B., Kasid, A., Gelmann, E.P., Davidson, N., McManaway, M., Huff, K., Bronzert, D., Bates, S., Swain, S., and Knabbe, C.: Autocrine and paracrine growth regulation of human breast cancer.

- J Steroid Biochem. 24(1) 147-154, 1986.
69. \*Gelman, E.P., Longo, D., Lane, H.C., Fauci, A.S., Masur, H., Wesley, M., Preble, O.T., Jacob, J., and Steis, R.: Combination chemotherapy for disseminated Kaposi's sarcoma in AIDS patients. *Am J Med.* 82:456-461, 1987.
  70. Dickson, R., Kasid, A., Huff, K., Bates, S.E., Knabbe, C., Bronzert, D., Gelmann, E.P., and Lippman, M.E.: Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17 $\beta$ -estradiol or v-H-ras oncogene. *Proc Natl Acad Sci, USA*, 84:837-841, 1987.
  71. Davidson, N.E., Gelmann, E.P., Lippman, M.E., and Dickson, R.B.: Epidermal growth factor receptor gene expression in estrogen-receptor positive and negative human breast cancer cell lines. *Molec Endocrin.* 1:216-223, 1987.
  72. \*Wilding, G., Chen, M., and Gelmann, E.P.: LHRH agonists and human breast cancer cells. *Nature* 329: 770, 1987.
  73. Lippman, M.E., Dickson, R.B., Gelmann, E.P., Rosen, N., Knabbe, C., Bates, S., Bronzert, D., Huff, K., Kasid, A.: Growth regulatory peptide production by human breast carcinoma cells. *J Steroid Biochem.* 30:53-61, 1988.
  74. \*Wilding, G., Lippman, M.E., and Gelmann, E.P.: Effects of steroid hormones and peptide growth factors on protooncogene c-fos expression in human breast cancer cells. *Cancer Res* 48:802-805, 1988.
  75. \*Freter, C., Lippman, M.E., Cheville, A., Zinn, S., and Gelmann, E.P. Alterations in phosphoinositide metabolism associated with 17- $\beta$  estradiol and growth factor treatment of MCF-7 breast cancer cells. *Molec Endoc.* 2:159-166, 1988.
  76. \*Zajac-Kaye, M., Gelmann, E.P., and Levens, D. A point mutation in the c-myc locus of a Burkitt lymphoma abolishes binding of a nuclear protein. *Science* 240: 1776-1780, 1988.
  77. Averbuch, S.D., Steakley, C.S., Young, R.C., Gelmann, E.P., Goldstein, D.S., Stull, R., Keiser, H.R. Malignant pheochromocytoma: Effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. *Ann Int Med* 109(4):267-273, 1988.
  78. \*Wilding, G., Zugmeier, G., Knabbe, C., Flanders, D., and Gelmann, E. Differential effects of transforming growth factor  $\beta$  on human prostate cancer cells in vitro. *Molecular and Cellular Endocrinology* 62:79-87, 1989.
  79. Heckford, S.E., Gelmann, E.P., and Matis, L.A. Distinct mechanisms of c-myc and lymphokine gene expression in an antigen-specific T cell clone. *Oncogene* 3:415-421, 1988.
  80. \*Wilding, G., Chen, M., and Gelmann, E.P. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. *The Prostate* 14:103-115, 1989.
  81. \*Sommers, C.L., Walker-Jones, D., Heckford, S.E., Worland, P., Valverius, E., Clark, R., McCormick, F., Stampfer, M., Abularach, S., and Gelmann, E.P. Vimentin expression in some hormone-independent breast cancer cell lines and in mammary epithelial cells transformed by two oncogenes. *Cancer Research* 49:4258-4263, 1989.
  82. \*King, C.R., Swain, S.M., Porter, L., Steinberg, S.M., Lippman, M.E. and Gelmann, E.P. Heterogenous expression of erbB-2 mRNA in human breast cancer. *Cancer Research* 49:4185-4191, 1989.



83. \*Wilding, G., Valverius, E., Knabbe, C., and Gelmann, E.P. Role of transforming growth factor- $\beta$  in human prostate cancer cell growth. *The Prostate* 15:1-12, 1989.
84. \*Sommers, C.L., Papageorge, A., Wilding, G., and Gelmann, E.P. The role of the rasH oncogene in the tumorigenesis of MCF-7 human breast cancer cells. *Cancer Res*, 50: 67-71, 1990.
85. \*Wilding, G., Gelmann, E.P., and Freter, C.E. Phosphoinositide metabolism in human prostate cancer cells in vitro. *The Prostate* 16: 15-27, 1990.
86. \*Voeller, H.J., Wilding, G., and Gelmann, E.P. v-rasH expression confers hormone-independent in vitro growth to LNCaP prostate carcinoma cells. *Molec Endoc*, 5: 209-216, 1991.
87. Wall, R.T., Gelmann, E.P., Hahn, M.B., and Jelenich, S.E. Monitored anesthesia care for laparoscopies in oncology patients. *Anesthesiol Rev*, 18: 43-48, 1991.
88. Sommers, C.L., Thompson, E.W., Torri, J.A., Kemler, R., Gelmann, E.P., and Byers, S.W. Absence of cell adhesion molecule uvomorulin expression in invasive human breast cancer cell lines. *Cell Growth Differen*, 365-372, 1991.
89. \*Gelmann, E.P. Oncogenes and growth factors in prostate cancer. *J NIH Res*, 3: 62-64, 1991.
90. Kahn, R.A., Kern, F.G., Clark, J., Gelmann, E.P., and Rulka, C. Human ADP-ribosylation factors: A functionally conserved family of GTP-binding proteins. *J Biol Chem*, 266: 2606-2614, 1991.
91. \*Gelmann, E.P., Thompson, E.W., and Sommers, C.L. Invasive and metastatic properties of MCF-7 cells and ras-H-transfected MCF-7 cell lines. *Int J Cancer*, 50: 665-669, 1992.
92. \*Dawson, N.A., Wilding, G., Weiss, R.B., McLeod, D.G., Linehan, W.M., Frank, J.A., Jacob, J.L., and Gelmann, E.P. A pilot trial of chemohormonal therapy for metastatic prostate carcinoma. *Cancer*, 69: 213-218, 1992.
93. Tarkington, M.A., Sommers, C.L., Gelmann, E.P., Tefft, M.C., and Lynch, J.H. The effect of pH on the in vitro colony forming ability of transitional cell carcinoma cells treated with various chemotherapeutic agents: implications for in vivo therapy. *J Urol* 147: 511-513, 1992.
94. \*Sommers, C.L., Heckford, S.E., Skerker, J.M., Worland, P., Torri, J.A., Thompson, E.W., Byers, S.W., and Gelmann, E.P. Loss of epithelial markers and acquisition of vimentin expression in adriamycin and vinblastine-resistant human breast cancer cell lines. *Cancer Res*, 52: 5190-5197, 1992.
95. \*Carroll, A.G., Voeller, H.J., Sugars, L., and Gelmann, E.P. p53 Oncogene mutations in three human prostate cancer cell lines. *The Prostate* 23: 123-134, 1993.
96. \*Voeller, H.J., Sugars, L.Y., and Gelmann, E.P. p53 oncogene mutations in primary human prostate cancer specimens. *J. Urology*, 151: 492-295, 1994.
97. \*Sommers, C.L., Skerker, J.M., Chrysogelos, S.A., and Gelmann, E.P. Regulation of vimentin transcription in human breast cancer cell lines. *Cell Growth and Diff*, 5: 839-846, 1994.
98. \*Sommers, C.L., Byers, S., Thompson, E., Torri, J.A., and Gelmann, E.P. Differentiation state and invasiveness of human breast cancer cell lines. *Br Cancer Res Trtmt*, 31: 325-335, 1994.

99. Sommers, C.L., Gelmann, E.P., Kemler, R., Cowin, P., and Byers, S.W. Alterations in  $\beta$ -catenin phosphorylation and plakoglobin expression in human breast cancer cells. *Cancer Res*, 54: 3544-3552, 1994.
- 100.\*Colomer, R., Bacus, S.S., Lupu, R., and Gelmann, E.P. ErbB-2 antisense oligonucleotides inhibit proliferation of breast carcinoma cells with erbB-2 oncogene amplification. *Br. J. Cancer*, 70: 819-825, 1994.
- 101.\*Berchem, G., Bosseler, M., Sugars, L.Y., Voeller, H.J., Zeitlin, S. and Gelmann, E.P. Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. *Cancer Res*, 55: 735-738, 1995.
- 102.\*Cardillo, M., Berchem, G., Tarkington, M.A., Krajewski, S., Krajewski, M., Reed, J., Tehan, T., Ortega, L., Lage, J. and Gelmann, E.P. Resistance to apoptosis and upregulation of Bcl-2 in benign prostatic hyperplasia after androgen deprivation. *J. Urol*, 158: 212-216, 1997.
- 103.Gumerlock, P.H., Chi, S.-G., Shi, X.-B., Voeller, H.J., Jacobson, J.W., Gelmann, E.P. and deVere White, R.W. p53 abnormalities in primary prostate cancer: SSCP analysis of cDNA detects rare mutant transcripts. *J Natl Cancer Inst*, 89:66-71, 1997.
- 104.He, W.W., Sciavolino, P.J., Wing, J., Augustus, M., Hudson, P., Meissner, P.S., Curtis, T., Shell, B., Bostwick, D.G., Tindall, D.J., Gelmann, E.P., Abate-Shen, C., and Carter, K.C. A novel human prostate-specific, androgen-regulated homeobox gene that maps to 8p21, a region frequently mutated in prostate cancer. *Genomics*, 43:69-77, 1997.
- 105.\*Voeller, H.J., Augustus, M., Madlike, V., Bova, G.S., Carter, K.C. and Gelmann, E.P. Coding region of NKX3.1, a prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers. *Cancer Research*, 57:4455-9, 1997
- 106.\*Stearns, V. and Gelmann, E.P. Does tamoxifen cause cancer in humans? *J Clin Oncol*, 16: 779-792, 1998.
- 107.Prorok, P.C., Andriole, G., Bresalier, R., Buys, S., Crawford, E.D., Fogel, R., Gelmann, E.P., Gilbert, F., Hasson, M., Hayes, R., Johnson, C.C., Mandel, J.S., O'Brien, B., Oken, M., Rafla, S., Reding, D., Rutt, W., Terasaki, P.I., Weissfeld, J.L., Yokochi, L., Gohagen, J.K. Design of the Prostate, Lung, Colon and Ovarian (PLCO) Cancer screening trial. *Controlled Clinical Trials*. 21:249S-406S, 2000.
- 108.\*Voeller, H.J., Truica, C.I. and Gelmann, E.P.  $\beta$ -catenin mutations in human prostate cancer. *Cancer Res*, 58:2520-2523, 1998.
- 109.\*Bowen, C., Spiegel, S. and Gelmann, E.P. Radiation-induced apoptosis mediated by retinoblastoma protein. *Cancer Res*, 58: 3275-3281, 1998.
- 110.\*Kimura, K., Bowen, C., Spiegel, S., and Gelmann, E.P. TNF- $\alpha$  sensitizes prostate cancer cells to  $\gamma$ -radiation-induced apoptosis. *Cancer Res*, 59: 1606-1614, 1999.
- 111.\*Bowen, C., Voeller, H.J., Kikly, K. and Gelmann, E.P. Synthesis of procaspases-3 and -7 during apoptosis in prostate cancer cells. *Cell Death and Differentiation*, 6: 394-401, 1999.
- 112.Mack, P.C., Gandara, D.R., Bowen, C., Edelman, M.J., Paglieroni, T., Schnier, J.B., Gelmann, E.P. and Gumerlock, P.H. Rb status as a determinant of response to UCN-01 in non-small cell lung carcinoma. *Clin Cancer Res*, 5:2596-2604, 1999.
- 113.\*Kimura, K. and Gelmann, E.P. TNF- $\alpha$  and Fas activate complementary FADD-dependent pathways that enhance apoptosis induced by  $\gamma$ -irradiation. *J Biol Chem*, 275: 8610-17, 2000.

- 114.\*Steadman, D.J., Giuffrida, D., and Gelmann, E.P. DNA binding sequence of the human prostate-specific homeodomain protein NKX3.1, *Nucleic Acids Research*, 28: 2389-2395, 2000.
- 115.Nava, V.E., Cuvillier, O., Edsall, L.C., Kimura, K., Gelmann, E.P., and Spiegel, S. Sphingosine enhances apoptosis of radiation resistant prostate cancer cells. *Cancer Res*, 60:4468-4474, 2000.
- 116.\*Truica, C., Byers, S., and Gelmann, E.P.  $\beta$ -Catenin affects androgen receptor transcriptional activity and ligand specificity. *Cancer Res*. 60: 4709-13, 2000.
- 117.\*Bowen, C., Bubendorf, L., Voeller, H.J., Slack, R., Willi, N., Sauter, G., Gasser, T.C., Koivisto, P., Lack, E.E., Kononen, J., Kallioniemi, O., and Gelmann, E.P. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. *Cancer Research*, 60:6111-5, 2000.
- 118.\*Kimura, K., Markowski, M., Bowen, C., Gelmann, E.P. Androgen blocks apoptosis of hormone-responsive prostate cancer cells. *Cancer Research*, 61:5611-18, 2001.
- 119.Gelmann, E.P., Chia, D., Pinsky, P.F., Andriole, G.L., Crawford, E.D., Reding, D., Hayes, R.B., Kramer, B.S., Woodrum, D.L., Gohagan, J.K., and Levin, D.L. representing the PLCO Screening Trial Investigators. Relationship of demographic and clinical factors to free and total PSA. *Urology*, 58:561-6, 2001.
- 120.\*Taylor, K.L., Shelby, R.A., Schwartz, M.D., Ackerman, J., LaSalle, V.H., Gelmann, E.P., & McGuire, C. The impact of item order on ratings of cancer risk perception. *Cancer Epidemiology, Biomarkers and Prevention*, 11:654-9, 2002.
- 121.Martin, M.B., Voeller, H.J., Gelmann, E.P., Lu, J., Stoica, E.G., Hebert, E.J., Reiter, R., Singh, B., Danielsen, M., Pentecost, E., Stoica, A. Role of cadmium in the regulation of AR gene expression and activity. *Endocrinology* 143:263-75, 2002.
- 122.\*Gelmann, E.P., Steadman, D.J., Ma, J., Ahronovitz, N., Voeller, H.J., Swope, S., Abbaszadegan, M., Brown, K., Strand, K., Hayes, R.B., and Stampfer, M.J. Occurrence of NKX3.1 C154T polymorphism in men with and without prostate cancer and studies of its effect on protein function. *Cancer Res*, 62:2654-9, 2002.
- 123.\*Kimura, K. and Gelmann, E.P. Propapoptotic effects of NF- $\kappa$ B in LNCaP prostate cancer cells lead to serine protease activation. *Cell Death and Differentiation*, 9:972-980, 2002.
- 124.\*Kimura, K., Markowski, M., Edsall, L., Spiegel, S., and Gelmann, E.P. Role of ceramide in mediating apoptosis in irradiated LNCaP prostate cancer cells. *Cell Death Differentiation*, 10:240-8, 2003.
- 125.\*Bowen, C., Birrer, M., and Gelmann, E.P. Retinoblastoma protein-mediated apoptosis after  $\gamma$ -irradiation. *J. Biol Chem*, 277:44969-79, 2002.
- 126.Gelmann, E.P., Bowen, C., and Bubendorf, L. Expression of NKX3.1 in normal and malignant tissues. *The Prostate*. 55:111-117, 2003.
- 127.Zellweger, T., Ninck, C., Mirlacher, M., Anfield, M., Glass, A.G., Gasser, T.C., Mihatsch, M.J., Gelmann, E.P., and Bubendorf, L. Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. *The Prostate*. 55:20-29, 2003.
- 128.\*Song, L., Herrell, R., Byers, S., Shah, S., Wilson, E.M., Gelmann, E.P.  $\beta$ -Catenin binds to the activation function-2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on

- ligand-dependent transcription. *Molec Cell Biol* 23:1674-1687, 2003.
- 129.\*Zhang, Y., Glass, A., Bennett, N., Oyama, K.A., Gehan, E., and Gelmann, E.P. Long-term outcomes after radical prostatectomy performed in a community-based health maintenance organization. *Cancer*, 100:300-307, 2004.
  - 130.\*Song, L.N., Coghlan, M., and Gelmann, E.P. Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. *Molec. Endoc.* 18:70-85, 2004.
  - 131.\*Taylor, K.L., Shelby, M.A., Gelmann, E., & McGuire, C. Quality of life and trial adherence among participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. *Journal of the National Cancer Institute*, 96:1083-94, 2004.
  - 132.Amin, A., Halabi, S., Gelmann, E.P., Stadler, W., Vogelzang, N., Small, E. 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901. *Urol. Oncol.* 22:398-403, 2004.
  - 133.\*Asatiani, E, Huang, W.-X., Wang, A., Ortner, A.R., Cavalli, L.R., Haddad, B.R. and Gelmann, E.P. Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer *Cancer Research*, 65:1164-73, 2005. Pub Med 15734999
  - 134.Andriole, G.L., Levin, D.L., Crawford, E.D., Gelmann, E.P., Pinsky, P.F., Chia, D., Kramer, B.S., Reding, D.R., Church, T.R., Grubb, R.L., Izmirlan, G., Ragard, L.R., Prorok, P.C., Gohagan, J.K. for the PLCO Project Team., Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: Findings from the Initial Screening Round of a Randomized Trial. *J Natl Cancer Inst, USA*, 97:433-8, 2005.
  - 135.Li, H., Zhang, Y., Glass, A., Zellweger, T., Gehan, E., Bubendorf, L., Gelmann, E.P., and Nevalainen, M.T. Activation of signal transducer and activator of transcription-5 (Stat5) in prostate cancer predicts early recurrence. *Clin Cancer Res*, 11:5863-8, 2005.
  - 136.\*Ortner, E.R., Hayes, R.B., Weissfeld, J. and Gelmann, E.P. The effect of homeodomain protein NKX3.1 R52C polymorphism on prostate gland size. *Urology*, 67:311-315, 2006.
  - 137.Hayes, R.B., Sigurdson, A., Moore, L., Peters, U., Huang, W.-Y., Pinsky, P., Reding, D., Gelmann, E.P., Rothman, N., Pfeiffer, R.M., Hoover, R.N., Berg, C.D., for the PLCO Trial Team. Methods for etiologic and early marker investigations in the PLCO trial. *Mutation Research*, 592:147-154, 2005.
  - 138.\*Song, L.-N. and Gelmann, E.P. Interaction of  $\beta$ -catenin and transcriptional intermediary factor-2/glucocorticoid receptor interacting protein-1 in transcriptional activation by the androgen receptor. *J Biol Chem* 280:37853-67, 2005, PMID: 16141201.
  - 139.\*Zheng, S.L., Ju, J.-H., Chang, B.-L., Ortner, E., Sun, J., Isaacs, S.D., Sun, J., Wiley, K.E., Liu, W., Zemedkun, M., Walsh, P.C., Ferretti, J., Gruschus, J., Isaacs, W.B., Gelmann, E.P., Xu, J. Germline mutation of NKX3.1 co-segregates with hereditary prostate cancer and alters the homeodomain structure and function. *Cancer Res.*, 66: 69-77, 2006.
  - 140.Gohagan, J.K., Marcus, P.M., Fagerstrom, R.M., Pinsky, P.F., Kramer, B.S., Prorok, P.C., Ascher, S., Bailey, W., Brewer, B., Church, T., Engelhard, D., Ford, M., Fouad, M., Freedman, M., Gelmann, E., Gierada, D., Hocking, W., Inampudi, S., Irons, B., Johnson, C.C., Jones, A., Kucera, G., Kvale, P., Lappe, K., Manor, W., Moore, A., Nath, H., Neff, S., Oken, M., Plunkett, M., Price, H., Reding, D., Riley, T., Schwartz, M., Spizarny, D., Yoffie, R. and Zylak, C. Final results of the Lung Screening Study, a randomized feasibility study of spiral CT

- versus chest X-ray screening for lung cancer, *Lung Cancer*, 47: 9-15, 2005.
141. Crawford, E.D., Pinsky, P.F., Chia, D., Kramer, B.S., Fagerstrom, R.F., Andriole, G., Reding, D., Gelmann, E.P., Levin, D.L., and Gohagan, J.K. Prostate specific antigen changes as related to the initial prostate specific antigen: data from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. *J. Urol* 175:1286-1290, 2006.
  142. Ju, J.H., Maeng, J-S., Zemedkun, M., Ahronovitz, A., Mack, J.W., Ferretti, J.W., Gelmann, E.P., and Gruschus, J.M. Physical and functional interactions between the prostate suppressor homeoprotein NKX3.1 and serum response factor. *J. Molec. Biol.*, 360:989-999, 2006.
  143. Bowen, C., Stuart, A., Ju, J-H., Tuan, J., Blonder, J., Conrads, T.P., Veenstra, T.D., and Gelmann, E.P. NKX3.1 homeodomain protein binds to topoisomerase I and enhances its activity. *Cancer Res*, 67:455-67, 2007. Pub Med 17234752.
  144. Pinsky, P.F., Miller, A., Kramer, B.S., Church, T., Reding, D., Prorok, P., Gelmann, E., Schoen, R.E., Buys, S., Hayes, R.B. and Berg, C.D. Evidence of a healthy volunteer effect in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, *Am J. Epidem.*, 165:874-81, 2007.
  145. Yeager, M., Orr, N., Hayes, R.B., Jacobs, K.B., Kraft, P., Wacholder, S., Minichiello, M.J., Fearnhead, P., Yu, K., Chatterjee, N., Wang, Z., Welch, R., Staats, B.J., Calle, E.E., Feigelson, H.S., Thun, M.J., Rodriguez, C., Albanes, D., Virtamo, J., Weinstein, S., Schumacher, F.R., Giovannucci, E., Willett, W.C., Cancel-Tassin, G., Cussenot, O., Valeri, A., Andriole, G.L., Gelmann, E.P., Tucker, M., Gerhard, D.S., Fraumeni, J.F.Jr, Hoover, R., Hunter, D.J., Chanock, S.J., Thomas, G. Genome-wide association study of prostate cancer identifies a second locus at 8q24. *Nature Genetics*, 39:645-9, 2007.
  146. Taylor, K.L., Cox, L.S., Zincke, N., Mehta, L., Mcguire, C., and Gelmann, E. Lung cancer screening as a teachable moment for smoking cessation. *Lung Cancer* 56: 125-134, 2007.
  147. Pinsky, P.F. Crawford, E.D., Kramer, B.S., Andriole, G.L., Gelmann, E.P., Grubb, R., Greenlee, R., Gohagan, J.K. Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial. *Brit J. Urol. Intl.* 99:775-9, 2007.
  148. Schumacher, F.R., Feigelson, H.S., Cox, D.G., Haiman, C.A., Albanes, D., Buring, J., Calle, E.E., Chanock, S.J., Colditz, G.A., Diver, W.R., Dunning, A.M., Freedman, M.L., Gaziano, J.M., Giovannucci, E., Hankinson, S.E., Hayes, R.B., Henderson, B.E., Hoover, R.N., Kaaks, R., Key, T., Kolonel, L.N., Kraft, P., Le Marchand, L., Ma, J., Pike, M.C., Riboli, E., Stampfer, M.J., Stram, D.O., Thomas, G., Thun, M.J., Travis, R., Virtamo, J., Andriole, G., Gelmann, E., Willett, W.C., Hunter, D.J. A common 8q24 variant in prostate and breast cancer from a large nested case-control study. *Cancer Res.* 67:2905-7, 2007.
  149. Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M, Barb D, Mantzoros C, Gelmann EP, Balk SP. A Phase II Study of Mifepristone (RU-486) in Castration Resistant Prostate Cancer with Correlative Assessment of Androgen related hormones. *BJU*. 101:1084-89, 2008, PMID: 18399827.
  150. Tan, S.H., Dagvadorj, A., Shen, F., Gu, L., Liao, Z., Abdulghani, J., Zhang, Y., Gelmann, E.P., Zellweger, T., Culig, Z., Visakorpi, T., Bubendorf, L., Kirken, R.A., Karras, J., Nevalainen, M.T. Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells. *Cancer Res* 68:236-48, 2008.
  151. Song, L-N. and Gelmann, E.P. Silencing mediator for retinoic and thyroid hormone receptor and nuclear receptor corepressor attenuate transcriptional activation by the  $\beta$ -catenin-TCF4 complex. *J. Biol. Chem.* 283:25988-25999, 2008, PMID: 18632669.

152. Markowski, M.C., Bowen, C., and Gelmann, E.P. Inflammatory cytokines induce phosphorylation and ubiquitination of prostate suppressor protein NKX3.1. *Cancer Res.* 68:6896-6901, 2008. Pub Med 18757402.
153. Muhlbradt, E., Asatiani, E., Ortner, E., Wang, A, and Gelmann, E.P. NKX3.1 activates expression of IGFBP-3 to mediate IGF-I signaling and cell proliferation. *Cancer Research*, 69:2615-22, 2009. Pub Med 19258508
154. Andriole, G.L., Crawford, E.D., Grubb, R.L. III, Buys, S.S., Chia, D., Church, T.R., Fouad, M.N., Gelmann, E., Kvale, P.A., Reding, D.J., Weissfeld, J.L., Yokochi, L.A., O'Brien, B., Clapp, J.D., Rathmell, J.M., Riley, T.L., Hayes, R.B., Berg, C.D., Kramer, B.S., Izmirlian, G., Miller, A.B., Pinsky, P.F., Prorok, P.C., and Gohagan, J.K. for the PLCO Project Team. Seven year mortality results and related findings from the prostate component of the PLCO randomized cancer screening trial. *New Engl J Med*, 360:1310-19, 2009, PMID: 1929756.
155. Crowell, J.M., Kramer, B.S., Kreimer, A.R., Prorok, P.C., Xu, J.L., Baker, S.G., Fagerstrom, R., Riley, T.L., Clapp, J.D., Berg, C.D., Gohagan, J.K., Andriole, G.L., Chia, D., Church, T.R., Crawford, E.D., Fouad, M.N., Gelmann, E.P., Lamerato, L., Reding, D., and Schoen, R.E. Cumulative incidence of false-positive results in repeated, multimodal cancer screening. *Annals of Family Med.* 7: 212-222, 2009.
156. Ju, Jeong Ho, Maeng, J-S., Lee, D-Y., Piszczek, G., Gelmann, E., Gruschus, J. Interactions of the acidic domain and SRF interacting motifs with the NKX3.1 homeodomain. *Biochemistry*, 48: 10601-7, 2009, PM 19780584.
157. Bowen, C. and Gelmann, E.P. NKX3.1 activates cellular response to DNA damage. *Cancer Research*, 70: 3089-97, 2010, PMID: 20395202.

### **Case Reports**

1. Weinstein, R.A., Gelmann, E.P., and Golomb, H.M.: Disseminated atypical mycobacterial infection in hairy cell leukemia. *Lancet* ii:1052-1053, 1978.
2. Gelmann, E.P., Costa, J., and Myers, C.: An aplastic sarcoma arising in a benign chondroblastoma. *Orthopedic Survey* 3:379-385, 1980.
3. Gelmann, E.P., Anderson, T.A., Jaffe, E., and Broder, S.: Chemotherapy for lymphoma in a patient with common variable immunodeficiency. *Arch Intern Med.* 142:90-92, 1982.
4. \*Gelmann, E.P. and Lack, E.J. DNA testing to refute the diagnosis of cancer. *New Engl J Med*, 337:1245-7, 1997.
5. Çetiner, H., Kır, G., Gelmann, E.P., Ozdemirli, M. Primary vulvar ewing's sarcoma/primitive neuroectodermal tumor: a report of two cases and review of the literature. *Int J Gynecol Oncol.* In press, 2008.

### **Reviews, Chapters and Editorials**

1. Declève, A., Niwa, O., Gelmann, E.P., and Kaplan, H.S.: Radiation activation of endogenous leukemia viruses in cell culture: Acute X-ray irradiation. Yuhas, J.M., Tennant, R.W., and Regan, J.D. (Eds.): *Biology of Radiation Carcinogenesis.* New York, Raven Press, 1976, pp. 217-225.
2. Leiberman, M., Declève, A., Gelmann, E.P., and Kaplan, H.S.: Biological and serological characterization of the C-type RNA viruses isolated from the C57B1/Ka strain of mice. II. Induction of propagation of the

- isolates. Kaplan, J.F. (Ed.): Radiation-induced Leukemogenesis and Related Viruses. INSERM. Symposium No. 4, Amsterdam, Elsevier North-Holland Biomedical Press, 1977, pp. 217-225.
3. Gallo, R.C., and Gelmann, E.P.: Editorial. In search of a Hodgkin's disease virus. *New Engl J Med.* 304:169-170, 1981.
  4. Westin, E.H., Wong-Staal, F., Gelmann, E.P., Baluda, M., Papas, T., Eva, A., Reddy, E.P., Tronick, S.R., Aaronson, S.A., and Gallo, R.C.: Expression of the *abl*, *myc* and *myb* genes in human hematopoietic cells. Yohn, D.S., and Blakeslec, J.R. (Eds.): *Advances in Comparative Leukemia Research 1981.* Amsterdam, Elsevier North Holland, Inc. pp. 405-406, 1982.
  5. Wong-Staal, F., Dalla-Favera, R., Gelmann, E.P., Westin, E., and Gallo, R.C.: Cloning of the simian sarcoma virus genome and its homologous human onc gene and studies on the expression of this gene in different human hematopoietic cells. Yohn, D.S., and Blakeslec, J.R. (Eds.): *Advances in Comparative Leukemia Research 1981.* Amsterdam, Elsevier North Holland, Inc. pp. 407-408, 1982.
  6. Wong-Staal, F., Josephs, S., Dalla-Favera, R., Westin, E., Gelmann, E.P., Franchini, G., and Gallo, R.C.: Cellular onc genes: The role as progenitors of viral onc genes and their expression in human cells. Neth, Gallo, Greaves, Moore, Winkler (Eds.): *Modern Trends in Human Leukemia.* Munich, Springer-Verlag, pp. 178-185, 1983.
  7. Dalla-Favera, R., Westin, E., Gelmann, E.P., Martinotti, S., Bregni, M., Wong-Staal, F., and Gallo, R.C.: The human onc gene *c-myc*. Structure, expression, and amplification in the human promyelocytic leukemia cell line HL-60. Neth, Gallo, Greaves, Moore, Winkler (Eds.): *Modern Trends in Human Leukemia,* Munich, Springer-Verlag, pp. 247-254, 1983.
  8. Wong-Staal, F., Westin, E., Franchini, G., Gelmann, E.P., Dalla-Favera, R., Manzari, V., and Gallo, R.C.: The cloning and analyses of human cellular genes homologous to retroviral onc genes. P. Chandra (Ed.): *Biochemical and Biological Markers of Neoplastic Transformation.* New York, Plenum Press, pp. 479-492, 1983.
  9. Wong-Staal, F., Sarngadharan, M.G., Gelmann, E.P., Arya, S., and Gallo, R.C.: Growth of human T-cells, T-cell growth factor, and human T-cell leukemia viruses. Golde, D.W., and Marks, P.A. (Eds.): *Normal and Neoplastic Hamatopoiesis.* New York, Alan R. Liss, Inc.1983.
  10. Wong-Staal, F., Franchini, G., Hahn, B., Arya, S.K., Gelmann, E.P., Manzari, V., and Gallo, R.C.: Human T-cell leukemia/lymphoma virus, *in vitro* transformation, and leukemia: some molecular studies. In Gallo, R.C., and Essex, M. (Eds.): *Human T-cell Leukemia/Lymphoma Viruses,* Cold Spring Harbor Laboratory, 1984, pp. 133-140.
  11. Gelmann, E.P., Franchini, G., Manzari, V., Wong-Staal, F., and Gallo, R.C.: Molecular cloning of a new unique human T-cell leukemia virus (HTLV-II<sub>MO</sub>). In Gallo, R.C., and Essex, M. (Eds.): *Human T-cell Leukemia/Lymphoma Viruses,* Cold Spring Harbor Laboratory, 1984, pp. 189-195.
  12. Gelmann, E.P., Popovic, M., Lomonico, A., Richardson, E., Sarin, P., Gallo, R.C.: Evidence of HTLV infection in two patients with AIDS. In Friedman-Kien, A., and Laubenstein, L.J. (Eds.): *AIDS: The Epidemic of Kaposi's Sarcoma and Opportunistic Infections.* New York, Masson Publishing USA INC., 1984, pp. 127-133.
  13. Ognibene, F.P., Shelhamer, J., Gill, V., Macher, A.M., Loew, D., Parker, M., Gelmann, E., Fauci, A.S., Parrillo, J.E., Masur, H.: The diagnosis of *Pneumocystis carinii* pneumonia in patients with the acquired immunodeficiency syndrome using subsegmental bronchoalveolar lavage. *Am Rev Respir Dis.* 129:929-932,

1984.

14. Lotze, M.T., Robb, R.J., Frana, L.W., Seipp, C.A., Sharrow, S.S., Longo, D.L., Gelmann, E.P., and Rosenberg, S.A.: Clinical studies with purified human IL-2 in patients with the acquired immunodeficiency syndrome and cancer. in *Acquired Immune Deficiency Syndrome*, Alan R. Liss, Inc., New York, pp. 409-423, 1984.
15. Gelmann, E.P., Wong-Staal, F., and Gallo, R.C.: The etiology of acute leukemia: Molecular genetics and viral oncology. In Wiernik, P., Canellos, G., Kyle, R., and Schiffer, C. (Eds.): *Neoplastic Diseases of the Blood*. New York, Churchill Livingstone, Inc., pp. 161-182, 1985.
16. Wong-Staal, F., Franchini, G., Hahn, B., Arya, S., Gelmann, E.P., Manzari, V., and Gallo, R.C.: Molecular Biology of HTLV. In Aaronson, S.A., Frati, L., Verna, R. (Eds.): *Genetic and Phenotypic Makers of Tumors*, Plenum Publishing Corp., pp. 337-344, 1985
17. Lane, H.C., Masur, H., Gelmann, E.P., and Fauci, A.S.: Therapeutic approaches to patients with AIDS. *Cancer Res.* 45 Suppl. 4674s-4676s, 1985.
18. Preble, O.T., Rook, A.H., Quinnan, G.V., Vilcek, J., Friedman, R.M., Steis, R., Gelmann, E.P., and Sonnabend, J. Role of interferon in AIDS. *Ann NY Acad Sci.* 437:65-75, 1984.
19. \*Longo, D.L., Steis, R., Lane, H.C., Lotze, M., Rosenberg, S., Preble, O., Masur, H., Rook, A., Fauci, A., Jacob, J., and Gelmann, E.P.: Malignancies in the AIDS patient: Natural history, treatment strategies, and preliminary results. *Ann NY Acad, Sci.* 437:421-430, 1984.
20. Lippman, M.E., Dickson, R.B., Gelmann, E.P., Kasid, A., Bates, S., Knabbe, C., Swain, S.M., McManaway, M., Wilding, G., Davidson, N., Huff, K., and Bronzert, D.: Mechanisms of growth regulation of human breast cancer. Proceedings of the 18th Mian symposium. *Advances in Gene Technology Molecular Biology of the Endocrine System*. Paett, D., Ahmeod, F., Beach, S., and Whelon, W.J. (Eds.), ICSU Short Reports, Vol. 4, pp. 254-257, 1986.
21. Lippman, M.E., Dickson, R.B., Gelmann, E.P., Knabbe, C., Kasid, A., Bates, S., and Swain, S.: Mechanisms of estrogenic and antiestrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Proceeding of the Symposium on Hormonal Manipulation of Cancer: Peptides Growth Factors and New(Anti)Steroidal Agents Rotterdam, The Netherland, June 4-6, 1986. Raven Press, New York, 1986.
22. Gelmann, E.P., Agnor, C., and Lippman, M.E., The role of the ras oncogene in human mammary cancer. in *Steroid Receptors in Health and Disease* ed. Moudgil, V.K. (New York: Plenum Press), 1988, p. 313-324.
23. Dickson, R.B., Knabbe, C., Bates, S.E., Huff, K., Davidson, N.E., Bronzert, D., Swain, S., Valverius, E., Gelmann, E.P., and Lippman, M.E. Growth factors, receptors and oncogenes in breast cancer. *Current Prospects in Breast Cancer* Mittra, I. and Desai, R. (Eds.) Bombay, India. Tata- McGraw Hill Publishing Company Ltd, 1988. p. 73-80.
24. Dickson, R.B., Rosen, N., Gelmann, E.P., and Lippman, M.E.: Oncogenes and Breast Cancer: Importance of receptor- and signal transduction-related protooncogenes. *Trends in Pharmacological Sciences*, 8: 372-5, 1987.
25. Zajac-Kaye, M., Avigan, M., Takimoto, M., Pittaluga, S., Quinn, J., Gelmann, E., Levens, D. Multifactorial regulation of the human c-myc oncogene. *Curr Top Microbiol Immunol.* 141:247-252, 1988.
26. \*Gelmann, E.P.: The role of laparoscopy in cancer management, in *Updates: Cancer - Principles and Practice*



- of Oncology. eds. Devita, V.T., Hellman, S. and Rosenberg, S.A., 1988, pp. 1-11.
27. Gelmann, E.P. and Lippman, M.E. Role of oncogenes in human breast cancer. in *The Breast*, eds. Bland, K.I. and Copeland, E.M. (W.B. Saunders, Philadelphia, PA). pp 351-362, 1991.
  28. Kern, F.G., Wellstein, A., Flamm, S., Zugmeier, G., Cheville, A., Lupu, R., McLesky, S., Gelmann, E.P., and Lippman, M.E. Secretion of heparin binding growth factors by breast cancer cells and their role in promoting cancer cell growth. *Cancer Chemotherapy: Challenges for the Future*, vol 5. Tokyo, Excerpta Medica, Ltd. 1990. p 167-174.
  29. \*Lippman, M.E. and Gelmann, E.P. Endocrine management of malignant disease. in *Endocrinology*, ed. DeGroot, L.I., Philadelphia: W.B. Saunders, Co. pp. 2846-2869, 1995.
  30. \*Gelmann, E.P. Androgen receptor mutations in prostate cancer. in *Drug Resistance*, ed. W.N. Hait. Boston, Massachusetts: Kluwer Academic Publishers, pp 285-304, 1996.
  31. \*Gelmann, E.P. Tamoxifen induction of apoptosis in ER-negative cancers: New tricks for an old dog? Editorial. *J Natl Cancer Inst*, 88: 224-226, 1996.
  32. \*Gelmann, E.P. Oncogenes in Human Breast Cancer. in *The Breast*, eds. Bland, K.I. and Copeland, E.M. Philadelphia: W.B. Saunders. 1998.
  33. \*Gelmann, E.P. Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma. *Semin Oncol* 24(Suppl 1):S1-65-S1-70, 1997.
  34. \*Gelmann, E.P. The molecular biology of the androgen receptor. *J Clin Oncol*, 20:3001-15, 2002.
  35. \*Liu, M. and Gelmann, E.P. P53 Gene Mutations: Case study of a clinical marker for solid tumors. *Semin Oncol*, 29:246-257, 2002.
  36. \*Gelmann, E.P. Searching for the gatekeeper of prostate cancer. *Crit. Rev. Oncol/Hematol* 46:S11-S20, 2003.
  37. \*Liu, M.C., Dickson, R.B., Lippman, M.E., and Gelmann, E.P. *Molecular Oncology of Breast Cancer*, in *The Breast*, third edition, eds. Bland, K.I. and Copeland, E.M. Philadelphia: W.B. Saunders. 2004.
  38. \*Mani, A. and Gelmann, E.P. The ubiquitin proteasome pathway and its role in cancer. *J Clin Oncol*. 21:4776-99, 2005.
  39. \*Gelmann, E.P. *Molecular Biology*. Chapter 2 in *Oncology MKSAP*. Alexandria, VA: American Society of Clinical Oncology. Editor: Cheson, B. pp21-56, 2004.
  40. \*Asatiani, E. and Gelmann, E.P. Targeted Therapies for Prostate Cancer. *Expert Opinion on Therapeutic Targets*, 9:283-98, 2005.
  41. Gelmann, E.P. and Semmes, O.J. Expression of genes and proteins specific for prostate cancer. *J Urol* 172:S23-27, 2004.
  42. \*Shand, R.L. and Gelmann, E.P. Molecular biology of prostate cancer pathogenesis. *Curr Opin Urol*. 16:123-131, 2006.
  43. Gelmann, E.P. Complexities of prostate cancer risk. *New Engl. J. of Med.*, 358:961-3, 2008.

44. Gelmann, E.P. and Muhlbradt, E.E. Molecular Biology of Prostate Cancer. In *Prostate Cancer: A Clinical Guide*. eds. Gulley, J.L., Dahut, W.L., Moul, J.W., and Sandler, H.M. Philadelphia: Lippincott, Williams, & Wilkins. 2008. pp 1-7.
45. Abate-Shen, C., Shen, M.M., and Gelmann, E. Integrating differentiation and cancer: The Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. *Differentiation* 76:717-727, 2008.
46. Gelmann, E.P. and Henshall, S.M. Clinically relevant prognostic markers for prostate cancer: the search goes on. *Ann. Int Medicine* 150:647-9, 2009.
47. Beildeck, M.E., Gelmann, E.P., and Byers, S.W. Cross-regulation of signaling pathways: An example of nuclear hormone receptors and the canonical Wnt pathway. *Exp Cell Res*. In press, 2010.

**Patents**

None

**Abstracts**

I did not record my published abstracts.

**Audiovisual/Media**

None